TRINITY BIOTECH PLC (TRIB) Form 424B3 — Jun 15, 2026
Trinity Biotech PLC filed a prospectus supplement registering a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD., allowing the company to sell up to $25 million in American Depositary Shares (ADSs) at a discount to market price. The agreement permits the company to issue up to 33.75 million ADSs (representing 675 million ordinary shares) to the investor, who will then resell them in the open market. The filing reveals significant financial distress, with total debt of $124.5 million and negative shareholders' equity of $72 million as of December 31, 2025.
Key figures
- Debt Amount
- 124555000
- Cash Position
- 5138000
- Gross Proceeds
- 25000000
- Shares Offered
- 33752429
- Shares Outstanding
- 405017380
- Lucid fee percent
- 3.75
- Ads to share ratio
- 1:20
- Commitment fee ads
- 175537
- Structuring fee usd
- 35000
- Exchangeable notes usd
- 210000
- Atm agreement limit usd
- 4350000
- Total debt adjusted usd
- 130920000
- Mico convertible note usd
- 16330000
- Registration expenses usd
- 50000
- Ordinary shares represented
- 675048580
- Warrants outstanding shares
- 66200000
- Perceptive conversion shares
- 3359019957
- Senior secured term loan usd
- 108015000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.